RUNX2 and osteosarcoma: By employing both 2D and 3D in vitro models using the aggressive SJSA-1 osteosarcoma cell line, we aim to elucidate the molecular mechanisms underlying this combination therapy, focusing on the protein kinase B (pAKT) and runt-related transcription factor 2 (RUNX2) signaling pathway.